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Abstract
Functional and structural alterations of clustered postsynaptic ligand gated ion channels in neuronal cells are thought to
contribute to synaptic plasticity and memory formation in the human brain. Here, we describe a novel molecular
mechanism for structural alterations of NR1 subunits of the NMDA receptor. In cultured rat spinal cord neurons, chronic
NMDA receptor stimulation induces disappearance of extracellular epitopes of NMDA receptor NR1 subunits, which was
prevented by inhibiting matrix metalloproteinases (MMPs). Immunoblotting revealed the digestion of solubilized NR1
subunits by MMP-3 and identified a fragment of about 60 kDa as MMPs-activity-dependent cleavage product of the NR1
subunit in cultured neurons. The expression of MMP-3 in the spinal cord culture was shown by immunoblotting and
immunofluorescence microscopy. Recombinant NR1 glycine binding protein was used to identify MMP-3 cleavage sites
within the extracellular S1 and S2-domains. N-terminal sequencing and site-directed mutagenesis revealed S542 and L790 as
two putative major MMP-3 cleavage sites of the NR1 subunit. In conclusion, our data indicate that MMPs, and in particular
MMP-3, are involved in the activity dependent alteration of NMDA receptor structure at postsynaptic membrane
specializations in the CNS.
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Introduction
The formation and the plasticity of synaptic structures of
neurons are regulated by diverse sets of molecular mechanisms.
Extracellular interactions of cell adhesion molecules and extracel-
lular matrix proteins play a crucial role in initiating synapse- and
receptor cluster formation by activating cellular signaling path-
ways [1]. Moreover, the activity of ligand gated ion channels
contributes to the regulation of structural alterations of synaptic
components. For example, it was shown that prolonged inhibition
of N-methyl-D-aspartate (NMDA) receptor subtype of excitatory
glutamate receptors can increase the number of NMDA receptor
clusters by altered trafficking and synaptic targeting of receptor
subunits in cultured neurons [2–4]. In general, these regulatory
processes are thought to be dependent on receptor mediated ion
fluxes, however, alteration of NMDA receptor numbers also
occurs upon conformational changes of subunits induced by
binding of the receptor coagonist glycine [5] to the extracellular
S1S2-region of NMDA receptor NR1 subunits [6,7].
The major structural determinants of targeting NMDA
receptors and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA) receptors to synapses are molecular signatures
at intracellular carboxy-terminal sequence motifs [8]. For
example, the two splice variants (NR1-C2 and NR1-C29) of the
carboxy-terminal region of the NMDA receptor NR1 subunits
determine differentially the number and localization of NMDA
receptor clusters in cultured neurons [3,4,9]. Interestingly, it was
shown recently that two proteins (ABP and GRIP) which interact
with the carboxy-terminus of AMPA receptors, bind to the
membrane-type 5 matrix metalloproteinase (MT5-MMP), thereby
directing MT5-MMP to growth cones and synaptic sites in
neurons, where the proteolytic activity of this protein may be
involved in remodelling of synapses by cleavage of cadherins and
matrix proteins [10].
In the present study we used cultured spinal cord neurons to
study alterations of postsynaptic NMDA receptor clusters under
conditions of prolonged NMDA receptor activation. Using
antibodies directed against extracellular or intracellular epitopes
of the NR1 subunit, we found that chronic NMDA receptor
activation leads to an exclusive loss of extracellular domains of
NMDA receptor NR1 subunits. Furthermore, our data indicate
that matrix metalloproteinase 3 is involved in proteolytic
cleavage of the extracellular glycine binding site of the NR1
subunit.
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Long lasting stimulation of cultured spinal cord neurons
with NMDA induces selective loss of NR1 extracellular
epitopes
To study the alteration of receptor clusters upon NMDA
stimulation we treated neurons cultured for 22 days in vitro,
(DIV22) for four days with 10 mM NMDA. Postsynaptic NMDA
receptors were analysed by immunofluorescence microscopy upon
single and double detection experiments with antibodies specific for
the presynaptic marker synaptophysin (detected with Cy3-conju-
cated second antibody, red fluorescence) and with antibodies
directed against the extracellular S2-domain of the NR1 glycine
binding site (Cy2-conjugated secondary antibody, green fluores-
cence). In another set of experiments we used anti-synaptophysin
staining in combination with antibodies specific for the intracellular
C2-domain of the NR1 subunit, one of two different splice variants
(C2 and C29) of the very carboxy-terminus and which is the major
splicevariantincultured spinalcordneurons[4].Inmatureneurons,
synaptophysin labelling is known to occur almost exclusively at
presynaptic boutons [13]. Therefore, the overlap of synaptophysin
and NR1-immunoreactivities is assumed to indicate postsynaptic
localization of NR1 subunits whereas extrasynaptic NR1 immuno-
reactivity appears independent of synaptophysin immunoreactivity.
We calculated the ratio of yellow puncta and the total number of
synaptophysin puncta for a dendritic length of 30 mmi n5 0c e l l s
from three different cultures for each experimental condition by
blinded analysis as apposition-index (AP-index) (Fig. 1A, B). When
comparing the number of synaptophysin puncta in control and
NMDA-treated cells, no changes in presynaptic bouton number
were observed. However, the number of punctated, synaptically
localized immunoreactivities detected with an antibody directed
against the extracellular domains of the NR1 subunit (NR1-S2) was
strongly decreased in NMDA-treated cells. Interestingly, the AP-
index was reduced from 0.6660.03 (mean6SEM; n=50 cells) for
control cultures to 0.2060.03 (mean6SEM; n=50 cells, p,0.001;
two-tailed t-test) upon prolonged NMDA receptor activation
(Fig. 1G). Unexpectedly, the analysis of cells which were stained
with synaptophysin antibody and an antibody directed against the
intracellular carboxy-terminus of the NR1 subunit (NR1-C2)
revealed that the punctate C2-immunoreactivity was still abundant
after NMDA treatment and in close apposition with synaptophysin
(Fig. 1C). This observation suggested the loss of S2-epitope of the
NR1 subunit while the carboxy-terminus was still localized in
postsynaptic membranes. In addition, NR1-specific immunoreac-
tivity which was not in apposition to synaptophysin was detected
with both antibodies (NR1-S2; NR1-C2), presumably representing
NR1 subunits within the dendritic compartment, however we
focussed our analysis on the pool of NR1 subunits overlapping with
synaptophysin immunoreactivity.
In order to directly compare the distribution of extracellular and
intracellular-epitopes and to verify the specificity of the NR1-S2
and NR1-C2-antibodies, we performed double detection experi-
ments with the two antibodies. These experiments revealed as
expected an almost complete overlap of both immunoreactivities
in control cultures (Fig. 1D). This observation is consistent with
former studies showing that the NR1 splice variant containing the
C2-cassette is the predominant version of the two alternative
carboxy-terminal isoforms NR1-C2 and NR1-C29 in this cell
culture system under control conditions (see also [4]). Consistent
with our previous results, the colocalization-index (ratio of yellow
signals and total S2-specific puncta) decreased drastically from
0.9160.03 (mean6SEM; n=5) in control cultures to 0.2360.02
(mean6SEM; n=5, p,0.0001; two-tailed t-test) upon NMDA
treatment (Fig. 1D, E). These data are in agreement with the
assumption that prolonged NMDA receptor stimulation leads to a
significant loss of extracellular NR1 epitopes.
To test whether receptor activation upon ligand binding could
induce masking of the S2-epitopes by conformational changes we
varied the duration of NMDA receptor stimulation. Interestingly,
already after two days of NMDA treatment a selective loss of
extracellular S2-epitopes was visible in double detection experi-
ments using NR1-S2 with either NR1-C2 or synaptophysin-
specific antibodies. The loss of S2-epitopes was not seen after one
day of NMDA receptor stimulation (data not shown), indicating
that the disappearance of S2-epitopes upon 2–4 days of NMDA
treatment is unlikely to result from a masking of S2-epitopes due to
agonist-induced conformational changes of receptor subunits,
because these conformational changes of epitopes should occur
with a short time of exposure to the ligand.
MMP activity is required for the NMDA-induced loss of
extracellular NR1-epitopes
The disappearance of extracellular NR1 epitopes while intracel-
lular C2-epitopes were preserved suggested that the ectodomains
might be cleaved off by proteolytic activity. Matrix metalloprotei-
nases (MMPs) are known to be involved in ectodomain shedding of
membrane proteins [14]. Therefore we treated the cultured neurons
with NMDA as before and added different inhibitors of matrix
metalloproteinases into the culture medium. The presence of MMP-
8 or both MMP-2 and MMP-9-inhibitors during NMDA stimulation
did not prevent the loss of extracellular NR1 epitopes (data not
shown). However, applying the MMP-inhibitor N-isobutyl-N-(4-
methoxyphenylsulfonyl)-glycylhydroxamic acid (NNGH, 1.3 mM)
for the last 2 or 3 days of NMDA treatment prevented the loss of S2-
epitopes. Under these conditions, the AP-index (ratio of yellow
signals and synaptophysin signals) was 0.6660.04 (mean6SEM;
n=50 cells) and 0.6660.03 (mean6SEM; n=50 cells), respectively
(Fig. 1F, G), i.e. very similar to control conditions. These results
suggested that blocking of MMPs other than MMP-2, MMP-8 or
MMP-9 prevented the cleavage of ectodomains of the NR1 subunit.
Interestingly, the presence of NNGH only at day 4 of the NMDA
treatmentwasnotsufficient torestore the postsynapticlocalization of
S2-epitopes (AP-index: 0.3460.03, mean6SEM; n=50 cells).
These data indicate that inhibition of MMPs for only one day in
culture may not be sufficient to detect newly synthesised NR1
subunits in the postsynaptic membrane in neurons that have lost
NR1 S2-epitopes.
PKC induced alteration of NR1 subunits is not dependent
on MMP-activity
To further analyse the observed NMDA induced loss of S2-
epitopes we used other experimental conditions to reduce the
number of NMDA receptor clusters. As described already for
hippocampal neurons [15], PMA-mediated activation of protein
kinase C (PKC) induced a fast reduction of the number of S2 and
C2-specific clusters also in spinal neurons. The AP-index was
reduced from 0.6560.03 (mean6SEM; n=5 cells) in control
cultures to 0.1960.02 (mean6SEM; n=5 cells, p,0.0001; two-
tailed t-test) and 0.1060.02 (mean6SEM; n=5 cells, p,0.0001;
two-tailed t-test) for S2 and C2-immunoreactivities, respectively.
Importantly, the disappearance of S2 and C2-epitopes was not
prevented by the presence of MMP-inhibitor NNGH (Fig. 2B, C).
These results are in agreement with the notion that the detected
C2-immunoreactivity is specific for NR1 subunits and that the
remaining C2-immunoreactivity after chronic NMDA stimulation
is due to the presence of remnant C2-epitopes.
NR1 Shedding by MMP-3
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NNGH was originally described as inhibitor of MMP-3 [16],
however, later other MMPs (for example MMP-10 or MMP-20)
were shown to be inhibited by NNGH, although the affinity of
NNGH for these MMPs are somewhat lower (43 fold and 6 fold
lower, respectively) [17–18]. In order to analyse whether MMP-3
might be a candidate protease for to cleave the NMDA receptor
NR1 subunit, we performed in vitro MMP-3 digestion assays with
activated MMP-3 and solubilized membrane proteins from rat
brain. As shown in Figure 3A, activated MMP-3 degraded
solubilized NR1 subunits of about 110–120 kDa. Moreover, the
presenceofMMP-inhibitorNNGHinthedigestionassaysprevented
proteolytic cleavage. An additional polypeptide of about 75 kDa is
also recognized by the used antibody and is also degraded, however,
whether this protein represents a NR1 fragment is not known.
Immunoblotting of the in vitro assays with a synaptophysin-specific
antibodyrevealedonlyaminordegradationofthisproteinindicating
that the NR1 subunit of the NMDA receptor is a rather specific
Figure 1. Chronic stimulation of spinal cord neurons with NMDA induces selective loss of extracellular epitopes due to MMP-3
activity. (A, B) At DIV26, cultured spinal neurons were fixed and stained with antibodies directed against NR1-S2 (green) and synaptophysin (red),
revealing a reduction of postsynaptic NR1 puncta (yellow) upon NMDA treatment. Scalebar is 10 mm. (C) NMDA treatment did not reduce apposition
of intracellular NR1-C2-epitopes (green) with synaptophysin (red), resulting in yellow signals. (D, E) Double-staining with NR1-S2 (green) and NR1-C2
(red) antibodies of control cells (D) and NMDA treated cells (E), show a selective loss of the extracellular NR1-S2 epitope upon receptor activation. (F)
Immunofluorescence of DIV26 neurons, which have been treated with 10 mM NMDA in the presence of MMP-3 inhibitor (3 days), reveals NR1-S2
epitope detection (green) appositioned with synaptophysin (red). (G) Plot of apposition indices after chronic stimulation of DIV22 neurons with
NMDA for 4 days. The reduction of apposition indices is prevented by MMP-3 inhibitor treatment for 3 (+3dI) or 2 days (+2dI), but not for 1 day (+1dI).
doi:10.1371/journal.pone.0002681.g001
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activation of MMP-3 in the in vitro digestion assays by immunoblot-
ting with an MMP-3-specific antibody, detecting the activated
MMP-3 protein (44/45 kDa) (Fig. 3B).
To further corroborate the possible identification of NR1 as a
MMP-3 substrate, we analysed MMP-3 and NR1-protein in
cultured spinal cord neurons by immunoblotting and/or immuno-
histochemistry. Consistent with the hypothesis that MMP-3 is
involved in the cleavage of NR1 ectodomains we detected the
activated forms of MMP-3 (45 and ,44 kDa) in addition to the
MMP-3 proprotein (59 kDa) by immunoblotting experiments with
total protein extracts from cultured spinal cord neurons. Densitom-
etry revealed that the level of the activated MMP-3 was slightly
increased upon NMDA treatment (1.5460.13 fold, mean6SEM;
n=12) (Fig. 3C). In addition, we isolated membrane fractions from
control cultures and from cultures treated with NMDA in the
absence and in presence of the MMP-inhibitor NNGH and
performed immunoblotting using anti-NR1-C2 together with anti-
NR1-C29-specific antibodies. In these experiments we detected a
polypeptide of about 60 kDa in membrane preparations of NMDA
treated spinal cord neurons but not from control cultures or upon
using NNGH together with NMDA (Fig. 3C). The detection of the
60 kDa polypeptide was improved byshorterblotting times resulting
in an incomplete transfer of ‘‘full-length’’ NR1-protein (Fig. 3D, left
panel). Using other blotting conditions, the ‘‘full-length’’ NR1
protein in control cultures was clearly seen (Fig. 3D, right panel, lane
6). Moreover, we detected a reduced amount of undigested NR1
protein from cells, which were treated with NMDA compared to
control conditions and those experiments in which NNGH-inhibitor
was included (Fig. 3D, right panel). However, further cleavage
reactions might occur, resulting in additional unstable proteolytic
products which could not be detected under the experimental
conditions which we used. Unfortunately, we could not detect N-
terminal fragments of the NMDA receptor within the conditioned
cellculturemedium.Thisispossiblyduetothelowabundanceorthe
instability of putative N-terminal-fragments.
To analyse the cellular expression of MMP-3 we used an MMP-
3-specific antibody for immunohistochemistry of cultured spinal
cord neurons (Fig. 4). Interestingly, MMP-3 immunoreactivity was
detected within the soma, the nucleus but also as discontinuous
staining in dendrites of cultured spinal cord neurons (Fig. 4A).
Control experiments without the MMP-3-specific antibody or with
preabsorbed MMP-3 antibody revealed only low background
staining (4B, C). The intensive nuclear staining detected in our
experiments is in agreement with data from different recent
publications showing convincingly that MMP-3 is localized in the
nucleus in different tissues and cultured cell types [19,20]. These
studies have shown that MMP-3 contains functional nuclear
localization signals and functions as transcription factor within the
nucleus [20].
Double staining experiments using MMP-3-specific and PSD-
95-specific antibodies showed that comparison of both immuno-
reactivities revealed only few overlapping puncta (Fig. 4, D–G),
suggesting that most MMP-3 protein is localized at sites within
dendrites distinct from PSD-95 containing synapses. In conclusion,
our data are in agreement with the notion that cultured spinal cord
neurons express MMP-3 which can be detected as proenzyme and
as activated protein.
MMP-3 cleaves the NR1 subunit within the glycine
binding site in vitro
In order to further prove that NMDA receptor NR1 subunits
might be cleaved by MMP-3, we performed in vitro MMP-3
digestion assays with activated MMP-3 and recombinant, soluble
protein (S1S2M) that contained the extracellular glycine ligand
binding site of the NR1 subunit (Fig. 5A) [12]. In order to detect
proteolytic fragments of the recombinant protein we used an anti-
S1S2 antibody and a penta-His antibody in immunoblot
experiments. The specificity of the S1S2-antibody was established
by immunoblotting experiments using isolated membranes from
rat brain and affinity purified IgGs from immunized rabbit serum
directed against S1S2 recombinant proteins (Fig. 5B). These
experiments demonstrated that the novel rabbit antibody
recognized the same major protein band of about 120 kDa which
was also detected by an other characterized mouse antibody [21]
specific for NMDA receptor NR1 subunits (Fig. 5B).
After incubation of recombinant S1S2M protein with active
MMP-3, we detected cleavage products of ,38 kDa, ,26 kDa,
Figure 2. Inhibition of MMP-3 does not prevent NMDA receptor removal from synapses induced by PKC activation. (A) At DIV26,
cultured spinal neurons were fixed and stained with an NR1-S2-specific antibody (green) and a synaptophysin-specific antibody (red), revealing a
large number of postsynaptic NR1 puncta (yellow). Scalebar is 10 mm. (B) At DIV26, cultured spinal neurons were stimulated with 100 nM PMA for
30 min in medium supplemented with NNGH to inhibit MMP-3 activity, fixed and stained with an NR1-S2-specific antibody (green) and a
synaptophysin-specific antibody (red), revealing a strong reduction of postsynaptic NR-S2 puncta (yellow) upon PKC activation. Scalebar is 10 mm. (C)
At DIV26, cultured spinal neurons were stimulated with 100 nM PMA in medium supplemented with NNGH to inhibit MMP-3 activity, fixed and
stained with an NR1-C2-specific antibody (green) and a synaptophysin-specific antibody (red), revealing also a strong reduction of postsynaptic NR1-
C2-specific puncta (yellow) upon PKC activation. Scalebar is 10 mm.
doi:10.1371/journal.pone.0002681.g002
NR1 Shedding by MMP-3
PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2681,20 kDa, ,18 kDa and ,14 kDa after SDS-PAGE and
Coomassie brillant blue staining (Fig. 5C). Immunoblotting with
an anti-penta-His antibody (Fig. 5C right pannel), revealed a
minor 26 kDa and a major 20 kDa protein fragment, which
suggests that these polypeptides span from the S1 region to the
His-tag at the carboxy-terminus of the S1S2 protein. Therefore
the cleavage sites must be within the S1 domain. The additional
fragments seen upon Coomassie staining (38 kDa, 18 kDa and
14 kDa) were identified as cleavage products of the S1S2 protein
using an anti-S1S2 antibody for immunoblotting (Fig. 5D). By
MALDI-TOF analysis, the 14 kDa and 18 kDa-fragments could
be attributed to the S1 and S2-domains of the S1S2 polypeptide,
respectively, because peptides obtained from these protein bands
upon trypsin digestion corresponded to the respective sequences of
the S1S2 protein (data not shown). In order to determine the
cleavage sites within the S1S2 protein N-terminal sequencing of
the 26 kDa, 20 kDa and 14 kDa fragments was performed. These
experiments revealed that the 14 kDa fragment exactly matches
the N-terminus of the expressed recombinant protein whereas the
analysis of the major cleavage product of 20 kDa identified a
serine within the S1 domain corresponding to serine 542 of the
NR1 subunit as amino-terminal amino acid of the 20 kDa
fragment and thus position S542 as one major MMP3 cleavage
site within the NR1 subunit. However, different attempts of N-
terminal sequencing of the 26 kDa protein band did not result in
an unambiguous amino acid sequence.
To further corroborate the identified site within the S1-region as
the MMP-3 cleavage site, we altered the encoded amino acid
sequence by site-directed mutagenesis of the expression construct.
With this approach we generated a fusion protein in which S542
(S178 of the S1S2 construct) was replaced by aspartate (mutant
S1S2Ser542). In addition, three amino acids arround serine 542
were replaced by different amino acid residues (see methods)
because these P3-P1 positions are known to contribute to the
specificity of MMP-3 cleavage [22]. The mutant S1S2Ser542
protein was expressed in E.coli, purified and renaturated as
described [12] and MMP-3 in vitro digestion experiments were
performed. As shown in Figure 6A the analysis of cleavage products
by immunoblotting with anti-S1S2 antibody showed that the
generation of the 20 kDa and 18 kDa-fragments by MMP-3
activity was completely abolished, suggesting that amino acids
spanning from P539 at the P3 position to Q541 at position P1 and
S542 at position P19 of the NR1 subunit may by important for
sequence-specific cleavage by MMP-3.
Figure 3. Analysis of MMP-3 and NR1 protein expression and digestion in cultured spinal cord neurons. (A) Upper panel: Solubilized
proteins from rat brain membranes were incubated with MMP-3 proprotein and activated MMP-3 in the absence or presence of MMP-3 inhibitor
NNGH and analysed by immunoblotting with a NR1-C29-specific antibody. MMP-3 was activated by aminophenylmercuric acetate (APMA). Digestion
of NR1 was prevented by the MMP-inhibitor NNGH. Lower panel: Immunoblot of the same probes with a synaptophysin-specific antibody (Syn.)
revealing no strong degradation of this protein. (B) Immunoblot of S1S2M digestion assays (15h) with an MMP-3-specific antibody, demonstrating
the presence of the active form of MMP-3 (45/44 kDa). (C) MMP-3 immunoblot of total protein extracts of cultured spinal cord neurons (DIV26) of
control cells (lane 1) and cells treated with NMDA (4 days, 10 mM) (lane 2); for comparison, MMP-3 pro-protein (10 ng) was separated in parallel on the
gel (lane 3). Lower panel: Immunoblot of the same gel as above probed with a b-tubulin antibody (loading control). (D) Detection of a 60 kDa
proteolytic NR1 polypeptide on NR1 immunoblots (left panel, lanes 1–5; and right panel lanes 6–8). NR1 proteins were detected after separation of
membrane proteins with SDS-PAGE and blotting using isolated membranes from spinal cord neurons cultured under control conditions (lane 3 and
lane 6), from neurons treated with NMDA in the absence (lane 4 and lane 7), and presence of MMP-3 inhibitor NNGH (lane 5 and lane 8). The left panel
was blotted with Na2-tetraborate buffer (Materials). Notice the clear detection of a protein band of about 60 kDa and the incomplete transfer of
marker proteins larger than 50 kDalton (Magic Marker, Invitrogen, containing a protein domain detected by the secondary antibody). The right panel
was blotted with methanol-containing buffer. Notice the clearer detection of an undigested NR1 protein band under these blotting conditions. Lanes
1 and 2 are loaded with protein molecular mass standards.
doi:10.1371/journal.pone.0002681.g003
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Coomassie staining of separated MMP-3 cleavage products, which
was not recognized by the anti-penta-His antibody, indicated that
one MMP-3 cleavage site should be localized near the very
carboxy-terminus of the S1S2 protein. Because the resulting short
C-terminal cleavage product was too small to be isolated by gel-
electrophoresis and to be analysed by N-terminal sequencing we
compared the corresponding region with regard to sequence
similarities with known MMP-3 cleavage sites of other proteins.
L790 of the NR1 subunit was selected as a candidate cleavage site
because leucine is the most conserved amino acid residue within
known MMP-3 cleavage sites. In addition, assuming L790 to be
positioned at the P19 site of a putative cleavage site, a proline and
an alanine would be positioned at P3 and P2 positions,
respectively, which again is a favoured configuration within
known MMP-3 cleavage motifs [22]. Therefore, we altered this
sequence motif by site-directed mutagenesis of the corresponding
expression construct, purified and renaturated the resulting
mutant S1S2Leu790 protein and performed in vitro MMP-3
digestion experiments. As seen in Figure 6B, the analysis of
cleavage products by immunoblotting experiments with anti-S1S2
-antibody showed that the 38 kDa and 18 kDa-protein fragments
could not be detected, whereas the detection of the 20 kDa
polypeptide was not altered. In addition, a band detected within
the control reaction running faster than the 26 kDa band was not
seen at the respective position with the mutant S1S2Leu790
protein. These results are consistent with the assumption that the
mutated sequence motif at the carboxy-terminus of the S1S2
protein constitutes a MMP-3 cleavage site. Thus, in the mature
NR1 subunit a second MMP-3 cleavage site should be localized
within the sequence P787-L790, most likely between T789 and
L790.
Discussion
In the present study we demonstrate that (i) prolonged NMDA
receptor stimulation resulted in the loss of extracellular epitopes of
the NMDA receptor NR1 subunit, (ii) blocking of MMPs activity
inhibited this process, (iii) MMP-3 specifically cleaved the NR1
protein in vitro, in particular the extracellular glycine binding
domains, (iv) S542 and L790 of the NR1 subunit are important
determinants of two MMP-3 cleavage sites within this NMDA
Figure 4. Expression of MMP-3 in cultured spinal cord neurons. (A) At DIV20, cultured spinal cord were fixed and stained with an MMP-3-
specific antibody, revealing MMP-3 expression in soma, nucleus and neurites of spinal cord neurons. Scalebar is 15 mm. (B) Control experiments
without first antibody using Cy3-conjugated anti-rabbit antibody. (C) Control experiments with anti-MMP-3 antibody which was preabsorbed with
MMP-3 protein. Pictures (A–C) were taken under the same conditions (D) PSD-95-immunofluorescence of spinal cord neurons. (E) MMP-3-
immunoreactivity of neurons shown in D. (F) Overlay of PSD-95 immunoreactivity (green) and MMP-3 immunoreactivity (red). Boxed region is shown
as enlargement in G. (G) Enlargement of dendritic region shown in F. Arrowheads indicate accumulations of MMP-3 immunoreactivities within a
dendrite. Arrow indicates overlapping PSD-95 and MMP-3-immunoreactivities. Scalebar is 15 mm (H) Control experiments using anti-mouse antibody
conjugated with Cy2. Scalebar is 15 mm.
doi:10.1371/journal.pone.0002681.g004
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teinase MMP-3 is involved in the shedding of ectodomains of the
NMDA receptor NR1 subunit. We identified at least three MMP-
3 cleavage sites within the S1 and S2-domains. One MMP-3
cleavage site could be determined by N-terminal sequencing at
position S178 of the S1S2 protein, corresponding to S542 of the
NR1 subunit, a position exactly N-terminal to the first NR1
transmembrane region. A second MMP-3 cleavage site was
identified in the carboxy-terminal region of the S1S2 protein,
corresponding to a position directly N-terminal to the fourth
transmembrane region of the NR1 subunit, consistent with the
observation that S2-specific epitopes are abolished upon prolonged
NMDA receptor activation. The proteolytic digestion of the NR1
subunit is likely to remove the cleaved domains of the glycine
binding pocket of the NMDA receptor and thereby renders the
receptor non-functional [23].
To our knowledge this is the first study showing that processing
of the extracellular domains of NMDA receptors by matrix
proteins could be involved in alteration of the NMDA receptor
structure. The identification of MMP-3 as a potential regulatory
component of synapse structure and function is consistent with the
increasing evidence that components of the extracellular matrix
play important roles in the regulation of neuronal connectivities.
For example, it is already well established that the perisynaptic net
of extracellular matrix components is important for determining
boundaries of axonal fields in the dentate gyrus [24]. Interestingly,
inhibition of MMP-3 and MMP-9 was shown recently to effect
spatial learning and synaptic plasticity in rats [25]. For the neuro-
muscular junction it was shown that MMP-3 specifically removes
agrin from the synaptic basal lamina [26], thereby regulating the
structure of the neuromuscular junction [27]. In the CNS, a
specific agrin isoform is expressed [28], which might be involved in
glutamatergic signaling [29]. Interestingly, also the neuronal
isoform of agrin is cleaved by MMP-3 in ischemic neuronal tissue
of rats after transient middle cerebral artery occlusion [30]. As it
was shown, that MMP-3 activation in neuronal tissue during
trauma-induced synaptogenesis is dependent on NMDA receptor
activity [31], it is conceivable that MMP-3 activation in vivo occurs
under conditions of extensive glutamate receptor activation,
similar to the conditions of extended stimulation of NMDA
receptors in our in vitro experiments. Indeed, more recently it was
shown that activated MMP-3 is released from apoptotic neuronal
Figure 5. In vitro digestion of NR1 subunits with MMP-3. (A) Schematic representation of the subunit transmembrane topology, of the
recombinant S1S2M protein and of the NR1 subunit. Black boxes indicate membrane domains and a grey box labels the specific carboxy-terminus,
generated by alternative splicing. (B) Immunoblot with separated proteins from rat brain membranes with the novel S1S2-specific antibody (rabbit)
(left site) and an NR1-S2-specific antibody (NMDAR, mouse, Chemicon). Both antibodies detect the NR1 subunit of about 120 kDa, in addition, a
smaller fragment of about 66 kDa is seen. (C) Left side: Coomassie brillant blue staining of S1S2 protein fragments upon MMP-3 digestion. Protein
fragments not seen in the control lane are indicated by arrowheads. The S1S2 protein is indicated by an arrow, and fragments are named according
to their apparent molecular weights. Right side: Immunoblot with an anti-penta-HIS-antibody after in vitro digestion of S1S2M by active MMP-3. A
major fragment of about 20 kDa and a minor fragment of about 26 kDa are indicated by arrows. (D) Immunoblot of S1S2M MMP-3 digestion
experiments analysed by immunoblotting with the S1S2-specific antibody; right: a schematic view of putative proteolytic S1S2 fragments.
doi:10.1371/journal.pone.0002681.g005
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proteolytically activated MMP-3 acts as signaling molecule to
activate microglia, which in turn might play a role in exacerbating
degenerative human brain disorders, such as Parkinson’s disease
[32]. One other study has identified the membrane-bound type 5
matrix metalloproteinase to interact with postsynaptic density
proteins and to be enriched at glutamatergic synapses, where it
may be involved in cleavage of the cell adhesion molecule
cadherin, thereby possibly contributing to synaptogenesis and
activity-dependent synaptic remodelling [10].
Classical substrates of MMP-3 include extracellular macromole-
cules likecollagen IV, elastinand fibronectin[33].Later studies have
identified additional substrates such as osteopontin [34] and SPARC
(Secreted Protein, Acidic and Rich in Cysteine), a glycoprotein that
modulates cell proliferation, adhesion, migration, and extracellular
matrix production [35]. Interestingly, the cleavage of extracellular
domains of transmembrane proteins like the CD95/APO-1/Fas
ligand could also be demonstrated [14]. The latter finding indicates
that MMP-3-dependent shedding of this signaling molecule is
involved in regulating apoptotic cell death.
Similarly, MMP-3 cleavage of the NMDA receptor NR1
subunit might be related to neuronal cell death. We propose a
model in which MMP-3 may be activated under conditions of
strong NMDA receptor stimulation in vivo and MMP-3-mediated
NR1 subunit inactivation by ectodomain shedding may antago-
nize the over-stimulation of the NMDA receptors in order to
prevent neuronal cell death. In addition, MMP-3 could be
involved in synaptic remodelling of excitatory synapses by cleavage
of extracellular matrix proteins. This process might be regulated
by NMDA receptor activity, as already indicated by different in
vivo studies [30,31]. Future research will reveal by which cellular
mechanisms the activity of MMP-3 is regulated and whether
MMP-3 may be released at specific synaptic sites in order to allow
local modifications of the perisynaptic network and of synaptic
proteins like neuronal agrin and NMDA receptors, thereby
contributing to increased synaptic plasticity.
Methods
Tissue preparation
Spinal cord neurons were prepared from embryonic stage 14
(E14) rats (Wistar and Sprague-Dawley (SD) strains; Charles
River, Sulzbach Germany) as described earlier [11]. Animal care
was in accordance with the European Communities Council
Directive (86/609/EEC) to minimize pain or discomfort. Spinal
cord neurons were plated on glass coverslips (14 mm, density:
5610
4 cells/well). Cells were maintained in culture medium
(Neurobasal medium with B27-supplement) (Gibco, Karlsruhe,
Germany) until the indicated time points (days in vitro; DIV).
Treatment of cells
Treatment of cells was performed for four days (DIV22–DIV26)
by daily addition of NMDA (final concentration 10 mM) into the
medium. The following MMP-inhibitors were used in a final
concentrations of ,10 fold of their individual Ki-values: MMP2/
MMP9 inhibitor ((2R)-2-((4-biphenylylsulfonyl)amino)-3-phenyl-
propionic acid) 3.25 mM, MMP8 inhibitor ((3R)-(+)-(2-(4-methox-
ybenzenesulfonyl)-1,2,3,4-tetrahydro-isoquinoline-3-hydroxamate)
50 nM and MMP-3 inhibitor (n-isobutyl-N-(4-methoxyphenylsul-
fonyl-glycylhydroxamic acid (NNGH)) 1.3 mM. All inhibitors were
purchased from Calbiochem.
Immunostaining
For immunostaining with NMDA receptor NR1 subunit-
specific antibodies cells were fixed and permeabilized on coverslips
using acetone (220uC) for 2 minutes. Unspecific binding was
blocked by incubation in 1% (w/v) bovine serum albumine (BSA)
in phosphate buffered saline (PBS) pH 7.9 at RT for 60 minutes.
Figure 6. Analysis of MMP-3 cleavage sites by site-directed
mutagenesis. (A) Immunoblot of S1S2 and mutant S1S2Ser542
protein fragments. S1S2 and mutant S1S2Ser542 proteins were purified,
incubated with active MMP-3 and separated by SDS-PAGE. Immuno-
blotting with anti-S1S2 antibody revealed that the mutations abolished
both the appearence of the 20 kDa and 18 kDa fragments (indicated by
arrows), suggesting that both fragments are generated from the same
N-terminal MMP-3 cleavage site. (B) Immunoblot of separated protein
fragments generated upon MMP-3 digestion of S1S2- and mutant
S1S2Leu790 proteins. Note the presence of three protein double bands
of 40/38 kDa, 26/24 kDa and 20/18 kDa in the S1S2 protein digestion
pattern (left), which are absent in the digestion pattern with mutant
S1S2Leu790 protein (indicated by arrows). Note that the cleavage site
generating the 20 kDa protein fragment (indicated by star) is not
effected by this mutation, lower panel: mutated MMP-3 cleavage site of
the S1S2Leu790 protein.
doi:10.1371/journal.pone.0002681.g006
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minutes at RT in a humidified chamber. For immunostaining with
a rabbit anti-MMP-3 antibody (Cat. No. M 4802, Sigma) spinal
cord neurons were fixed with methanol (220uC) for 10 minutes.
Unspecific binding was blocked with 1% (w/v) BSA and 5% horse
serum (v/v),0.15%(v/v) TritoninPBS for 1h at RT.Anti-NMDAR
antibody (NR1-S2) (mouse, Cat. No. MAB363, 1:100) and anti-
NR1-C2 antibody (rabbit, Cat. No. AB5050P, 1:50) were purchased
from Chemicon (Temecula, USA). Anti-PSD95 antibody (mouse,
Cat. No. 05. 494, 1:500) was purchased from Upstate. Anti-
synaptophysin antibodies (rabbit, Cat. No. 101 002, Synaptic
Systems, Go ¨ttingen, Germany), (mouse, SVP-38, Cat. No. S 5768,
Sigma, Taufkirchen, Germany) were used at final dilutions of 1:200.
Theantibodiesweredilutedasindicatedin1xPBS(pH 7.9)with1%
(w/v) BSA prior to use. Coverslips were washed three times
(5 minutes each) in PBS and incubated with fluorochrome
(Alexa488, Cy2, Cy3)-conjugated secondary antibodies for 30 min-
utes in a dark humidified chamber. After three additional washes in
PBS (pH 7.9, 5 minutes each) in the dark, coverslips were mounted
in Mowiol and stored at 4uC in the dark until microscopical
evaluation. Secondary antibodies were from Molecular Probes
(Eugene, USA). All secondary antibodies were used at final dilutions
of1:800inPBSwith1%(w/v)BSA.Stainingexperimentswithoutor
with ‘‘cross-species’’-primary antibodies were performed to ensure
the specificity of the secondary antibodies. Preabsorbtion of anti-
MMP-3 antibody was done in 1:10 molar excess of MMP-3 protein
for 30 minutes at RT.
Microscopical evaluation
Images of NMDA receptor analysis were recorded using a Leica
TCS-NT confocal laser scanning microscope equipped with a
1006oil-immersion lens (Leica) with a numerical aperture of 1.35.
An argon-krypton laser was used for excitation with 488 nm and
568 nm lines and emission-windows were set to 500 nm–535 nm
and 585 nm–620 nm, for the detection of green and red
fluorescence, respectively. Laser intensities and photo-multiplier
settings were used in a way that no cross-excitation was detected.
Images were recorded in a sequential channel mode and were
acquired as multiple Z-slices using an image size of 102461024
pixels. Individual sections were scanned twice and averaged to
optimize signal-to noise ratios. Extended focus projections were
calculated from individual sections and used to generate overlays
of both fluorescence channels. The apposition index was
calculated as ratio of yellow puncta and total synaptophysin
specific (red and yellow) puncta or as colocalization index of C2
and S2-imunoreactivities as ratio of yellow puncta and total S2-
specific puncta. MMP-3 detection experiments were analysed
using a Zeiss Axiovert 200M motorized microscope (Zeiss, Jena,
Germany) attached to a SPOT cooled CCD camera (Visitron
Systems, Puchheim, Germany). All images were collected using
636or 1006Plan-Neofluar oil objectives.
Statistical analysis
Statistical analysis was performed using the GraphPad-Prism IV
software as indicated in the Results section. Values of p,0.05 were
considered as significant.
Isolation of membranes from cultured neurons and
solubilization of membrane proteins from rat brain
For preparation of membranes from cultured spinal cord
neurons, cells were washed three times with PBS-N (Gibco) and
subsequently scraped off from 6 well-plattes using a disposable cell
scraper (Greiner) with 0.5 ml/well potassium-phosphate buffer
(25 mM), pH 7.0. containing a mixture of proteinase-inhibitors
(protease inhibitor complex complete, Boehringer, Germany;
phosphoramidon (330 mg/ml) and GM6001, 2.6 mM). Cells were
homogenized using a Potter-Elvehjem glass homogenizer at 4uC.
The homogenate was centrifuged first for 15 min (4uC, 1.0006g)
and the supernatant was again centrifuged for 45 min at 4uCa t
120.0006 g. The membrane pellet was resuspended in 26
Laemmli SDS-PAGE loading buffer. For total protein extracts,
cells were lysed directly on the cell culture dish with 46Laemmli
SDS-PAGE loading buffer.
For solubilization of membrane proteins rat brains (1 g, adult
rat, Wistar) were homogenized using a Potter-Elvehjem glass
homogenizer at 4uC in 50 mM Tris-HCl, pH 9.0. The homog-
enate was centrifuged first for 15 min (4uC, 1.0006 g) and the
supernatant was then centrifuged for 30 min at 4uC at 30.0006g.
The membrane pellet was resuspended in 50 mM Tris pH 9.0
supplemented with 1% (w/v) deoxycholate. Solubilization of
membrane proteins was performed for 1 hr at 37uC with
permanent shaking. Non-solubilized material was cleared by
ultracentrifugation at 100.0006g for 1 hr at 4uC.
Site-directed mutagenesis
The plasmid expression construct S1S2M [12] was used as a
template for site-directed mutagenesis. Note that the construct
includes threonine 543 of the S1 domain, numbering counts the
amino acid position of the putative mature protein assuming that
the sequence Arg-Ala-Ala represents the first three N-terminal
amino acids upon cleavage of the signal peptide of the NR1
subunit. Site-directed mutagenesis was performed using the
‘‘Quick Change XL-Site-Directed Mutagenesis Kit’’ (Stratagene,
USA). The sequences of all constructs were verified by DNA
sequencing. For generation of mutant S1S2Ser542 the following
sense oligonucleotide together with the respective complementary
anti-sense oligonucleotide was used: 59-gagcacactggactcatttatg-
cagcgtcattgggacaccgagggtggggtcaatgccgaag-39. The encoded se-
quence of mutant construct contained the amino acid sequence
Arg
539-His-Trp-Asp
542 replacing the sequence Pro
539-Phe-Gln-
Ser
542 of the ‘‘wild type’’ S1S2M protein sequence. For the
construction of mutant S1S2Leu790 we used the following sense
oligonucleotide 59-gactcccgcagcaatgctcctacatgggacgcttttgagaaccat-
caccaccatc-39 together with the complementary anti-sense oligo-
nucleotide, resulting in an alteration of four amino acid positions
surrounding L790: Ala
788-Thr-Leu-Thr




In vitro MMP-3 digestion
Solubilized membrane proteins were treated with 4 M urea,
50 mM Tris pH 7.0 for 0.5 hr at 37uC, dialyzed at 4uC against
2.500 volumes of MMP-3 digestion buffer (50 mM Tris-HCl
pH 7.5, 200 mM NaCl, 10 mM CaCl2, 20 mM ZnCl2) for 2.5 h.
MMP-3 (100 ng, Chemicon, Temecula, USA) was activated with
1.5–5 mM 4-aminophenyl-mercuricacetat (APMA) for 2 hr at
37uC and subsequently incubated with 50 mg of resuspended
membrane proteins in a final volume of 20 ml for 15 hr at 37uC.
Reactions were stopped by adding SDS-PAGE loading buffer and
reaction products were analysed by SDS-PAGE and immunoblot-
ting. Recombinant S1S2M protein was expressed in E. coli,
isolated and renaturated as described [12] dialysed against 2.500
volumes of MMP-3 digestion buffer and denaturated protein was
separated by ultracentrifugation at 100.0006 g for 1 h at 4u C.
Soluble protein (750 ng) was incubated with 75 ng of APMA-
activated MMP-3 (2 h, 37uC) or with 75 ng MMP-3 catalytic
domain (Calbiochem) for 4–15 h at 37u C.
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spectrometry
N-terminal sequencing of S1S2-fragments was performed by a
commercial supplier (TopLab, Martinsried) using a proteinse-
quencer Procise 492 (Applied Biosystems). MALDI-TOF mass
spectrometry analysis was performed by the core facility for Mass
Spectrometry and Proteomics (ZMBH, University of Heidelberg).
Generation of an anti-S1S2 antibody
S1S2 protein was expressed in E. coli, purified and renaturated as
described [12] and used for immunisation of rabbits (BioScience,
Go ¨ttingen, Germany). The IgG fraction was purified by salt
precipitation of sera obtained from final bleedings after two booster
antigen injections and subsequently by immunopurification using
S1S2proteinboundtoSulfo-link
TMmatrix(Pierce,Rockford,USA).
Monospecific antibodies were stored in 50% (w/v) glycerol stocks at
220u C and used for immunoblotting at a dilution of 1:200.000.
Immunoblot analysis
Products of in vitro MMP-3 digestion, protein extracts from
cultured spinal cord neurons and proteins from isolated mem-
branes from cultured spinal cord neurons were separated by 10%
polyacrylamide (w/v) SDS-gels or 4%–12% (w/v) polyacrylamide
gradient NuPAGE gels (Invitrogen, Carlsbad, CA, USA) and
proteins were blotted on polyvinylidene difluoride (PVDF)
membranes (Millipore, Billerica) according to the manufacturers’
instructions using either Na2-tetraborat buffer (10 mM) or SDS-
PAGE -running buffer supplemented with 20% methanol.
Membranes were probed with anti-NR1-C2 antibody (rabbit,
1:2000, AB5050P, Chemicon, Temecula, USA), anti-S1S2
antibody (rabbit, 1:40.000), anti-Penta-His-antibody (mouse,
1:10.000, Qiagen), anti-synaptophysin antibody (rabbit, 1:10.000,
Cat. No. 101 002, Synaptic Systems, Go ¨ttingen, Germany) and
mouse anti-b tubulin antibody (1:50.000, Cat. No. T 0198, Sigma,
Taufkirchen, Germany). MMP-3 proteins were detected with
mouse anti-MMP-3 antibody (1:4.000, MAB1339, Chemicon,
Temecula, USA). HRP-linked secondary antibodies were visual-
ized using ECL-Plus (Amersham Pharmacia, Freiburg, Germany).
After exposure films were developed and signals were scanned and
analysed using Kodak Digital science 1D software.
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